Introduction
============

The incidence of malignant melanoma is increasing rapidly worldwide ([@b1-ijmm-41-05-2687]). Despite notable progress in melanoma research, treatment options for advanced stages of the disease remain limited and the mortality rate in advanced melanoma is significantly higher than in other skin tumors ([@b1-ijmm-41-05-2687]).

The tumor stroma represents an important component in the structure of malignant tumors. This microenvironment may significantly influence their biological properties, including metastatic potential ([@b2-ijmm-41-05-2687]). The powerful effect of this microenvironment has also been observed in malignant melanoma via convincing models, where melanoma cells acquired properties of melanocyte precursors (neural crest cells) following grafting to vertebrate embryos ([@b3-ijmm-41-05-2687]). The embryonic microenvironment here eliminates their ability to form tumors ([@b3-ijmm-41-05-2687]). Intercellular crosstalk between different cell types occurring in melanoma ([@b4-ijmm-41-05-2687],[@b5-ijmm-41-05-2687]) may be relevant for tumor biology in general.

As fibroblasts represent a fundamental component of various tissues, they also have an indispensable role in cancer ([@b2-ijmm-41-05-2687]). The broad biological activity of melanoma-associated fibroblasts (MAFs) has been described and notably, they are also able to stimulate other cancer types than melanoma *in vitro* ([@b4-ijmm-41-05-2687],[@b6-ijmm-41-05-2687]-[@b9-ijmm-41-05-2687]). MAFs, as well as other cancer-associated fibroblasts, express smooth muscle actin (SMA) ([@b10-ijmm-41-05-2687],[@b11-ijmm-41-05-2687]) in the majority of tumor types ([@b2-ijmm-41-05-2687]). The transition of fibroblasts to SMA-expressing myofibroblasts is primarily stimulated by transforming growth factor-β1 (TGF-β1), which is frequently elevated in sera of melanoma patients. An additive effect of endogenous lectin, galectin-1, has also been reported in this context ([@b10-ijmm-41-05-2687]-[@b12-ijmm-41-05-2687]).

The present report details the comparison of MAFs prepared from a cutaneous melanoma metastasis and autolo-gous control fibroblasts (ACF) from non-cancerous skin of the same patient. The former was isolated prior to therapy initiation, and the latter was isolated during B-Raf inhibitor therapy, yet before the onset of computed tomography (CT)-documented disease progression. Such a matched pair of stromal fibroblasts of human origin is notably rare for analysis. The data obtained from cell cultures are compared with immunohistochemical analysis of sections from the melanoma metastasis including the expression of TGF-β1. The effect of this cytokine on normal dermal fibroblasts prepared from the skin of healthy donors was also examined.

Material and methods
====================

Case report, tissue collection and processing
---------------------------------------------

The patient, a 76 year-old Caucasian female who was diagnosed with acrolentiginous melanoma of the left sole (Breslow, 4.0 mm; Clark, IV) ([@b13-ijmm-41-05-2687]) in 2004, was recruited in January 2011 at the Department of Dermatology and Venereology, First Faculty of Medicine, Charles University (Prague, Czech Republic). CT scanning was used throughout observation of the patient ([Fig. 1](#f1-ijmm-41-05-2687){ref-type="fig"}), and 7 years following wide surgical excision, multiple metastases were detected on the lateral parts of the chest and in axillary lymph nodes ([Fig. 1A](#f1-ijmm-41-05-2687){ref-type="fig"}). One cutaneous metastasis on the chest was surgically removed for histologic confirmation ([Figs. 1A](#f1-ijmm-41-05-2687){ref-type="fig"} and [2](#f2-ijmm-41-05-2687){ref-type="fig"}) of the disease relapse and also for B-Raf V600E mutation screening. MAFs were isolated from the same tumor mass using a previously described method ([@b14-ijmm-41-05-2687],[@b15-ijmm-41-05-2687]). B-Raf V600E mutation was confirmed ([Fig. 3](#f3-ijmm-41-05-2687){ref-type="fig"}) and treatment with the B-Raf inhibitor vemurafenib was initiated. Following 3 months of vemurafenib therapy, unaffected skin from the anatomically comparable site ([Fig. 1B](#f1-ijmm-41-05-2687){ref-type="fig"}) was harvested via punch biopsy to isolate ACFs. At this stage, partial response was achieved using RECIST criteria ([@b16-ijmm-41-05-2687]). Following further 6 months, CT documented rapid disease progression and the patient succumbed to mortality 5 months later.

Control dermal fibroblasts (CDF) were prepared from anatomically comparable chest skin of three healthy Caucasian women donors (aged 35-42 years), undergoing aesthetic surgery (recruited at the same department between March 2011 and September 2013). All tissue samples used in the present study were obtained following the provision of explicit written informed consent, with a protocol reviewed by a local ethics committee (FWA 00003027; General University Hospital, Prague, Czech Republic) with full respect to the Declaration of Helsinki. Institutional consent for publication and data maintenance was also issued.

Cell culture
------------

MAFs, ACFs and CDFs were isolated from tissue samples as described previously ([@b14-ijmm-41-05-2687],[@b15-ijmm-41-05-2687]). Passage 3 or 4 cells were used in the present study for analysis. For immunocytochemistry, RNA and DNA studies, fibroblasts were cultured for 5 days before they reached subconfluent monolayers in Dulbecco\'s modified Eagle\'s medium containing 10% fetal bovine serum and antibiotics (penicillin/streptomycin; 10.0 U/ml and 10.0 *μ*g/ml, respectively; all, Biochrom, Ltd., Cambridge, UK) at 37°C and 5% CO~2~. To evaluate the induction of SMA in CDF, TGF-β1 (R&D Systems, Inc., Minneapolis, MN, USA) was supplemented to the culture medium at 10 ng/ml ([@b11-ijmm-41-05-2687]).

B-Raf sequencing
----------------

For DNA extraction, paraffin-embedded formalin-fixed (4% formaldehyde in PBS for 24-48 h at room temperature) tissue sections (thickness, 5 *μ*m) were deparaffinized using sequential washes with xylene and absolute ethanol. Sections were digested using proteinase K and DNA was extracted using NucleoSpin FFPE DNA (both, Machery-Nagel GmbH, Düren, Germany), according to the manufacturer\'s protocol. DNA extraction from fibroblasts was performed using TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) according to the manufacturer\'s protocol. The concentration of DNA was measured using a fluorometer Qubit 2.0 (Invitrogen; Thermo Fisher Scientific, Inc.).

DNA extracted from MAFs was selectively amplified to generate a 224-bp sequence of *BRAF* exon 15 using polymerase chain reaction (PCR) with the following primers: Forward, 5′-TCATAATGCTTGCTCTGATAGGA-3′ and reverse, 5′-GGCCAAAAATTTAATCAGTGGA-3′ ([@b15-ijmm-41-05-2687]). A total of 30 ng DNA was amplified with 0.1 *μ*M each primer, 160 *μ*M deoxynucleotide triphosphates, 2 mM MgCl~2~, 0.3 U Gold AmpliTaq Perkin Polymerase, and 1X PCR Buffer II (10 mM Tris-HCl pH 8.3, 50 mM KCl) in a final volume of 15 *μ*l (both from Thermo Fisher Scientific, Inc). Cycling conditions were as follows: Denaturation step at 94°C for 2 min and at 95°C for 20 sec followed by 5 cycles of denaturation at 95°C for 20 sec, annealing at 62.5°C for 30 sec and primer extension at 72°C for 1 min; 35 cycles of denaturation at 95°C for 20 sec, annealing at 57.5°C for 30 sec and primer extension at 72°C for 1 min; and one final run-off extension at 72°C for 10 min ([@b16-ijmm-41-05-2687]). PCR was performed in a TGradient 96 thermocycler (Biometra GmbH, Göttingen, Germany). PCR products were visualized via 1.5% agarose gel electrophoresis in 0.5X Tris-borate-EDTA buffer (Thermo Fisher Scientific, Inc). Subsequently, the PCR products were purified using an Agencourt AMpure XP (Beckman Coulter, Inc., Brea, CA, USA) and sequenced using forward primers of the PCR amplification and a DTCS Quick Start kit according to the manufacturer\'s protocol (Beckman Coulter, Inc). The cycle sequencing conditions consisted of 30 cycles of 96°C for 20 sec, 50°C for 20 sec, and 60°C for 4 min. The PCR products were re-purified using an Agencourt CleanSEQ kit (Beckman Coulter, Inc.) according to the manufacturer\'s protocols, sequenced on a CEQ 8000 sequencing machine (Beckman Coulter, Inc.), and analysed using CEQ 8000 sequencing software. Sequence traces were compared with *BRAF* reference sequence (NM_004333.4; <https://www.ncbi.nlm.nih.gov/nuccore/NM_004333>).

Immunohistochemistry and immunocytochemistry
--------------------------------------------

Immunohistochemistry was routinely performed using the avidin-biotin complex method. Briefly, tissue was fixed for 24-48 h in 4% formaldehyde (in PBS) at room temperature and embedded in paraffin. Tissue sections (5-um tick; rehydrated through xylene and ethanol) were washed with PBS with 0.2% Tween-20, and heat-induced epitope retrieval was performed in citrate buffer (pH 6.0, in autoclave at 120°C for 3 min with slow gradual cooling for 60 min. All chemicals for immunohistochemistry were supplied by Sigma-Aldrich (Merck KGaA, Darmstadt, Germany). Tissue sections were blocked using Protein Block system (Dako; Agilent Technologies, Inc., Santa Clara, CA, USA; cat. no. X0909) at room temperature for 10 min according to the manufacturer\'s protocol, followed by 3% hydrogen peroxide (in PBS) treatment for 20 min (all from Sigma-Aldrich; Merck KGaA). Consequently sections were incubated overnight at 4°C with biotinylated antibodies directed against SMA (1:100; Dako; Agilent Technologies, Inc.; cat. no. M0851; clone 1A4), and TGF-β1 (1:100, Bioss Antibodies, Inc., Woburn, MA, USA; cat. no. bs-0086). A Dako Streptavidin Peroxidase kit (including 50X 3,3′-diaminobenzidine- horseradish peroxidase substrate buffer) was used for visualization of immunohistochemical reaction according to the manufacturer\'s protocol (Dako; Agilent Technologies, Inc.; cat. no. K5001). Nuclei were counterstained with hematoxylin and mounted in permanent mountant.

The cultured cells on coverslips were briefly fixed in 2% paraformaldehyde in PBS for 5 min at room temperature and permeabilized with Triton X-100 (Sigma-Aldrich; Merck KGaA). Antibodies against SMA (1:100; mouse monoclonal; Dako; Agilent Technologies, Inc., cat.no. M0851; clone 1A4) and fibronectin (1:1,000; rabbit polyclonal; Dako; Agilent Technologies, Inc.; cat. no. A0245) were used to detect protein levels, via incubations for 2 h at room temperature. Blocking was performed in 10% goat serum for 30 min at room temperature. Results of immunocytochemical reaction were visualized using tetramethylrhodamine-conjugated goat anti-rabbit (cat. no. T5393; 1:250) and fluorescein isothiocyanate-conjugated goat anti-mouse antibody (cat. no. AP307F; 1:250; both, Sigma-Aldrich; Merck KGaA) for 60 min at room temperature). Nuclei were counterstained with DAPI for 1 min at room temperature (Sigma-Aldrich; Merck KGaA).

The negative control of all staining procedures was performed by replacement of primary antibody with appropriate isotype control (Universal Negative Control; mouse cat. no. N1698; rabbit cat. no. N1699; Dako; Agilent Technologies, Inc.). Following mounting in Vectashield (Vector Laboratories, Inc., Burlingame, CA, USA) samples were analyzed at ×200 magnification using an ECLIPSE-90i fluorescence microscope (Nikon Corp., Tokyo, Japan) equipped with suitable filter blocks, a charge-couple device camera (Vosskühler, Osnabrück, Germany) and a system for computer-assisted image analysis (LUCIA 5.1, Laboratory Imaging s.r.o., Prague, Czech Republic).

Transcriptome analysis
----------------------

Total RNA was isolated from MAFs, ACFs and CDFs using an RNeasy Micro kit (Qiagen Sciences, Inc., Gaithersburg, MD, USA) according to the manufacturer\'s protocol. Quality and concentration of RNA were measured with a NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific, Inc.). RNA integrity was analysed using an Agilent Bioanalyzer 2100 (Agilent Technologies, Inc.). Only samples with an intact RNA profile were used for expression profiling analyses (RNA Integrity Number \>9).

Illumina HumanHT-12 v4 Expression BeadChips (Illumina, Inc., San Diego, CA, USA) were used for the microarray analysis following the standard protocol. Briefly, 200 ng RNA was amplified with the Illumina TotalPrep RNA Amplification kit (Ambion; Thermo Fisher Scientific, Inc.) and 750 ng labelled RNA was hybridized on the chip according to the manufacturer\'s protocol. Analysis was performed in four (CDF, 2 donors) and two (MAF and ACF) replicates per group. The raw data were preprocessed using GenomeStudio software (version 1.9.0.24624; Illumina, Inc.) and the limma package ([@b19-ijmm-41-05-2687]) of Bioconductor ([@b20-ijmm-41-05-2687]), as described previously ([@b21-ijmm-41-05-2687]). The transcription profiles were background corrected using a normal-exponential model, quantile normalized and variance stabilized using base 2 logarithmic transformation. Moderated t-test was used to detect differentially expressed transcripts within limma ([@b19-ijmm-41-05-2687]). False discovery rates (FDR) were used to select significantly differentially transcribed genes (FDR \<0.05), as presented in [Table I](#tI-ijmm-41-05-2687){ref-type="table"}. Principal components analysis (PCA) was performed using the made4 ([@b22-ijmm-41-05-2687]) package of the Bioconductor on expression data of the genes that were found differentially expressed in at least one of the comparisons.

Genome methylation analysis
---------------------------

Genomic DNA was isolated using the aforementioned standard techniques and purified using a Qiagen DNeasy kit (Qiagen Sciences, Inc.) according to the manufacturer\'s protocol. Quality and concentration of DNA were measured with a NanoDrop 1000 spectrophotometer (Thermo Fisher Scientific, Inc.). Bisulfite conversion was performed using an EZ DNA Methylation kit (Zymo Research Corp., Irvine, CA, USA).

Illumina Infinium HumanMethylation27 BeadChips (Illumina, Inc.) were used for microarray analysis following the manufacturer\'s protocol. In brief, 400 ng bisulphite-converted DNA was amplified using an Infinium Methylation Assay kit (Illumina, Inc.) and 750 ng of labelled DNA was hybridized on the chip according to the manufacturer\'s procedure. The analysis was performed in two replicates per group (MAF, ACF and CDF). The raw data were preprocessed using GenomeStudio software to obtain methylated and unmethylated probe intensities, and the Bioconductor ([@b20-ijmm-41-05-2687]) package methylumi to background correct and normalize the data, and to calculate M-values according to the following formula: M=log~2~((methylated_probe_intensity + 100)/(unmethylated\_ probe_intensity + 100)). The positions of CpG islands were previously retrieved in human genomic DNA by Wu *et al* ([@b23-ijmm-41-05-2687]). CpG shores (and shelves) were defined as 2-kbp regions that flanked CpG islands (or shores, respectively).

Moderated t-test implemented in the limma package ([@b19-ijmm-41-05-2687]) was used to detect differentially methylated genomic regions (DMR) based on change in M-value and false discovery rate (FDR\<0.1, δM\>1). PCA of the methylation data was performed using the made4 package on M-values of regions that were considered DMR in at least one comparison.

The MIAME compliant expression and methylation data were subsequently deposited to the ArrayExpress database (accessions E-MTAB-4964 and E-MTAB-4965; <https://www.ebi.ac.uk/arrayexpress/browse.html>).

Gene set enrichment analysis (GSEA)
-----------------------------------

GSEA was performed using Enrichr ([@b24-ijmm-41-05-2687]). Briefly, differentially expressed genes and differentially methylated genomic regions, respectively, that were specific for MAF or CDF were uploaded to the Enrichr web interface (<http://amp.pharm.mssm.edu/Enrichr/>). The analysis was performed with default parameters and with equal weight on each gene (or genomic region, in cases of methylation). Analysis of various gene set collections was performed, including the gene ontology (GO) terms and KEGG pathways, only the analysis of the GO terms, and in particular the biological process ontology, are reported. Other analyses resulted in the identification of similar gene sets. For expression data, the 20 best terms (i.e. those with the greatest significance) for each comparison are reported in [Table II](#tII-ijmm-41-05-2687){ref-type="table"}. The selection roughly corresponds to the terms with an adjusted P-value of the enrichment test of P\<0.03. The analysis of DMRs did not result in any significantly enriched GO terms.

Results
=======

Properties of fibroblasts isolated from the patients
----------------------------------------------------

Fibroblasts in cutaneous metastasis ([Fig. 2A](#f2-ijmm-41-05-2687){ref-type="fig"}) exhibited SMA ([Fig. 2B](#f2-ijmm-41-05-2687){ref-type="fig"}) and immunohistochemistry also revealed that melanoma cells in this metastasis were rich in TGF-β1 ([Fig. 2C](#f2-ijmm-41-05-2687){ref-type="fig"}). MAFs isolated from this metastasis were not harbouring the B-Raf V600E mutation ([Fig. 3A](#f3-ijmm-41-05-2687){ref-type="fig"}). The isolated MAFs in culture exhibited a high cytoplasmic signal of fibronectin and were also sporadically positive for SMA ([Fig. 4A](#f4-ijmm-41-05-2687){ref-type="fig"}).

This observation was in contrast with ACFs isolated from the normal skin of the same patient following 3 months on vemurafenib, where numerous clusters of SMA-positive myofibroblasts were present *in vitro* ([Fig. 4B](#f4-ijmm-41-05-2687){ref-type="fig"}). The expression of fibronectin was similar in MAFs ([Fig. 4A](#f4-ijmm-41-05-2687){ref-type="fig"}) and ACFs ([Fig. 4B](#f4-ijmm-41-05-2687){ref-type="fig"}).

In the control experiment performed with CDFs, sparse extracellular fibres of fibronectin were observed, but no myofibroblasts were detected ([Fig. 4C](#f4-ijmm-41-05-2687){ref-type="fig"}). As TGF-β1 was detected in the melanoma metastasis and because the elevation of TGF-β1 in sera of melanoma patients was documented previously ([@b10-ijmm-41-05-2687]), the effect of TGF-β1 on CDFs was assessed. TGF-β1 was able to markedly stimulate the transition of fibroblasts to myofibro-blasts and also increase fibronectin production ([Fig. 4D](#f4-ijmm-41-05-2687){ref-type="fig"}).

Comparison of expression profiles of MAFs, ACFs, and CDFs
---------------------------------------------------------

The expression profiles of MAFs, ACFs and CDFs were compared using microarrays ([Fig. 5A--D](#f5-ijmm-41-05-2687){ref-type="fig"} and [Table I](#tI-ijmm-41-05-2687){ref-type="table"}). The expression profiles differed between MAFs and ACFs in the expression of 1,800 genes, and between MAFs and CDFs there were 2,701 deregulated genes. Finally, there were 1,314 deregulated genes between ACFs and CDFs (FDR\<0.05). Among the genes upregulated in the comparison of MAF and CDF cells, hyaluronan synthase 1 and desmoglein 2, which are both associated with extracellular matrix (ECM) formation, and cytokeratins 18 and 81 were identified. MAF cells exhibited decreased expression of chemokine CXCL12. In comparison of MAFs with ACFs, upregulation of hyaluronan synthase 1 and desmoglein 2 was observed, together with another ECM component, COL10A1. ACF showed upregulation of CXCL12 and cardiac-muscle and smooth-muscle actins (ACTC1 and ACTG2). ACTG2 was also upregulated in ACFs compared with CDFs, where the upregulation of the following Wntsignalling pathway related genes was also observed: Frizzled family receptor 4 and naked cuticle homolog 2.

Principal component analysis was performed to visualize associations between the analysed groups ([Fig. 5A](#f5-ijmm-41-05-2687){ref-type="fig"}): The location of the groups in the plot and the number of deregulated genes between the groups demonstrated that ACFs differ greatly from CDFs. The association between ACFs and other analysed groups were further analyzed ([Fig. 5B and C](#f5-ijmm-41-05-2687){ref-type="fig"}). Two sets of deregulated genes were defined: a) Genes deregulated in both MAFs and ACFs, and in both MAFs and CDFs; and b) genes deregulated in both ACFs and CDFs, and in both MAFs and CDFs. To identify biological processes deregulated in a) MAFs and b) ACFs and MAFs, GSEA was performed on the respective sets ([Table II](#tII-ijmm-41-05-2687){ref-type="table"}).

Genes deregulated similarly in ACFs and in CDFs (in comparison with MAFs; set a) participate in control of biological processes related to cell migration and motility (GO:0051272, 2000147, 0030335 and 0048598), morphogenesis, ECM structure (GO:0048729, 0030198 and 0043062), and response to stress factors, including decreased oxygen level (GO:0070482, 0036293, 0071294 and 0001666). At the gene level, the activity of, e.g. CXCL12 and FGF13, were upregulated and was CXCL5 downregulated in ACFs and CDFs in comparison with MAFs.

ACFs share deregulated genes with MAFs (in comparison with CDFs; gene set b), which are associated with changes in angiogenesis and endothelial cell proliferation (GO:0001525, 0001936, 0001936, 0045765, 0045765, and 0001937), ECM structure (GO:0030198 and 0043062), response to wounding (GO:0002237), positive regulation of cell motility and locomotion (GO:2000147 and 0040017), ossification (GO:0001503), and regulation of the Wnt signaling pathway (GO:0030111 and 0060828). At the gene level, marked upregulation of interleukin (IL)6, VEGFA, and TGFB3 genes and downregulation of TGFA was observed in MAFs and ACFs as compared to CDFs. The relevant differentially regulated genes were consequently validated directly at the protein level, therefore quantitative-PCR was not used for validation.

Changes in DNA methylation in MAFs, ACFs and CDFs
-------------------------------------------------

To evaluate whether the changes in transcription activity of differently expressed genes were associated with epigenomic changes of the fibroblasts, differentially methylated genomic regions (DMRs) were detected between the cultured fibroblasts using microarray technology. A total of 2,300 DMRs were detected between MAFs and ACFs (787 genes affected in CpG islands, 985 genes affected in CpG shores), between MAFs and CDFs there were 2,908 DMRs (966 genes affected in CpG islands, 1159 genes affected in CpG shores), and finally there were 1,835 DMRs between ACFs and CDFs (649 genes affected in CpG islands, 751 genes affected in CpG shores; FDR\<0.1, \|logFC\|\>1; [Fig. 5E--H](#f5-ijmm-41-05-2687){ref-type="fig"}; [Table III](#tIII-ijmm-41-05-2687){ref-type="table"}). PCA analysis ([Fig. 5E](#f5-ijmm-41-05-2687){ref-type="fig"}) distinguished ACF cells from CDFs and indicated that they differ from either MAFs or CDFs, respectively ([Fig. 5H](#f5-ijmm-41-05-2687){ref-type="fig"}). MAFs displayed hyper-methylation of genomic regions associated with an SMA (ACTA2) and fibroblast growth factor binding protein 2 (FGFBP2). The latter was specifically hyper-methylated in MAF cells. ACTA2 was hypo-methylated in normal CDF cells when compared with both MAF and ACF cells.

As in the gene expression analysis, the association between ACFs and other analysed groups was evaluated ([Fig. 5F and G](#f5-ijmm-41-05-2687){ref-type="fig"}) and two sets of deregulated regions were defined: a) Those differentially methylated in both MAFs and ACFs, and MAFs and CDFs, and b) the genes differentially methylated in both ACFs and CDFs, and MAFs and CDFs. GSEA was performed on the respective gene sets. Notably, although there is a large number of DMRs and associated genes, GSEA did not yield significant enrichment of any single GO term (except the general term \'behavior\', which is unrelated to the studied phenomenon). Still, it was observed that the genes attributed to the GO terms affected by changes in gene transcription were widely present among DMRs. For MAF specific genes (set a), the GO terms typically contained 25 DMRs (min 23, max 70), with the exception of a single GO term (GO:0071294) with only 3 DMRs. For CDF specific genes (set b), the terms typically contained 17 DMRs (min 7, max 34), with the exception of the GO term GO:0001937 with two DMRs only. Therefore, it may be concluded that, although changes in methylation are not specifically targeted on biological processes manifested by changes in the expression activity, they target these processes to a large degree.

At the gene level, the largest changes in methylation of these selected genes were observed: Actins ACTA1 and ACTA2, the genes coding for SMA; growth factors FGF11, FGF22, and BMP8B; and chemokines and interleukins CXCL12, IL6, and IL32.

Finally, the expression profiles ([Fig. 6A](#f6-ijmm-41-05-2687){ref-type="fig"}) and methylation profiles ([Fig. 6B](#f6-ijmm-41-05-2687){ref-type="fig"}) were evaluated, together with the selected genes with strongest changes in gene expression: Actins ACTC1 and ACTG2; growth factors FGF13, BMP6, and TGFA; chemokines and interleukins CXCL5, -6, -12, IL1B, IL6, IL8, IL11, and IL24; and keratin KRT7. Notably, the expression profiles of the selected genes in ACF samples are typically closer to expression profiles observed in CDF samples, whereas their methylation status is, in general, closer to MAFs ([Fig. 6](#f6-ijmm-41-05-2687){ref-type="fig"}).

Discussion
==========

In skin, normal fibroblasts represent a number of distinct differentiated mesenchymal cell types that have different origins, locations and functions ([@b25-ijmm-41-05-2687],[@b26-ijmm-41-05-2687]). Furthermore, similar heterogeneity is observed in tumor stromal tissues. The myofibroblast ([@b27-ijmm-41-05-2687]), which is a hallmark of cancer stroma, remains one of the most poorly understood cell types. It is clear that current understanding of the myofibroblast (its origins, functions and molecular regulation) will have a profound influence on the future effectiveness of regenerative medicine, tissue engineering and cancer therapy.

To exclude site-specific differences in e.g. gene transcription or DNA methylation, low passage fibroblasts obtained from the comparable anatomically defined region, the upper trunk, were used. Based on this restriction, relatively high homogeneity in gene transcription of CDFs, even from various donors, can be demonstrated.

In the present study, MAFs did not share B-Raf mutations with melanoma cells from skin metastasis. This suggests a likely local origin from the dermis, rather than the epithelial-to-mesenchymal transition from malignant cells. This also excludes MAFs as the primary target of the direct effect of B-Raf inhibitor.

Via the comparison of MAFs and CDFs from healthy donors, distinctive differences were observed. Recruitment of normal dermal cells in the vicinity of melanoma and their conversion to MAFs is classically associated with TGF-β release from melanoma cells in a paracrine manner ([@b27-ijmm-41-05-2687]). Notably, ACFs from the same melanoma patient also greatly differed from CDFs from the general population. All gene expression profile differences were confirmed directly on the protein level, therefore omitting the necessity of quantitative-PCR.

The comparison of expression profiles of MAFs, ACFs and CDFs indicated that ACFs exhibit higher activity of the genes responsible for activation of fibroblasts and cancer cells, namely important mediators such as TGF-β or IL6. ACFs also demonstrated deregulation of ACTG2 expression, and of another gene associated with smooth muscle, KCNMA1.

The presence of activated fibroblasts in normal dermis far from the melanoma lesions supports that melanoma is a systemic disease. This idea was initially proposed by Krasagakis *et al* ([@b12-ijmm-41-05-2687]). Furthermore, the present patient was treated with a B-Raf inhibitor which is known to induce cytokine release from melanoma cells *in vitro* ([@b27-ijmm-41-05-2687]). The observed unusual activation of ACF cells may be explained in a similar manner as activation of MAF via production of bioactive substances, namely TGF-β, IL6, IL8, and matrix metalloproteinase-1 by cancer cells in consequence to vemurafenib treatment ([@b28-ijmm-41-05-2687]-[@b32-ijmm-41-05-2687]).

TGF-β signalling is one of the major pathways controlling cell and tissue behaviour in development and in various human pathologies. During tumorigenesis, TGF-β has a dual role as tumor suppressor and tumor promoter ([@b33-ijmm-41-05-2687]). Important functions of this pathway have previously been described in a context-dependent manner both in epithelial cancer cells and in the tumor microenvironment during tumor progression ([@b28-ijmm-41-05-2687],[@b30-ijmm-41-05-2687],[@b33-ijmm-41-05-2687]). The TGF-β system signals via protein kinase receptors and SMAD mediators. Alterations of the TGF-β signaling pathway are implicated in numerous types of human cancer ([@b33-ijmm-41-05-2687]).

Notably, differential expression of genes in the TGF-β signalling pathway (e.g. SMAD molecules, etc.) have not been observed, despite the fact that the TGF-β signalling pathway serves an important and key role in the tumor microenvironment and cancer progression. This reflects the dependence of SMADs on their phosphorylation status, rather than actual quantity. Furthermore, TGF-β signalling is always reported as \'context-dependent\' ([@b27-ijmm-41-05-2687],[@b28-ijmm-41-05-2687],[@b30-ijmm-41-05-2687]). In such cases, the critical point is availability of the cytokine (TGF-β) in the tumor tissue.

In a recent study, Fedorenko *et al* ([@b28-ijmm-41-05-2687]) concluded that B-Raf inhibitor treatment escape in melanoma is due to short-term adaptation in which cells evade the immediate effects of the drug in the supportive microenvironment. However, confirmation of relevancy of this murine model for human pathology was (to the best of our knowledge) missing. The present study offers a comparison of this murine model to paired dermal fibroblasts isolated from a single melanoma patient prior to systemic therapy (B-Raf inhibitor) initiation and on treatment. Such paired material is rarely available and the present data is of relevance to the above-mentioned animal model.

The present data suggests a more sustained effect as the ACF cultures were stored without vemurafenib for a substantial duration (≥2 months) during expansion *in vitro*. Maintenance of this activated phenotype would require more profound cellular changes, e.g. on the epigenetic level. Although dependence of the gene methylation and its expression is complex, and both gene upregulation and downregulation may occur with gene methylation ([@b33-ijmm-41-05-2687]), the observed increase of IL6 expression in ACFs may be associated with the observed demethylation of this gene in ACFs. Similarly, an increased expression of keratin 7 was observed in ACFs and MAFs accompanied by its decreased methylation. This unusual presence of simple type keratins in activated fibroblasts has also been described elsewhere ([@b34-ijmm-41-05-2687]).

Notably, observed upregulation of SMA expression in ACF cells at the protein level and the transcriptional activation of ACTA2, the gene coding for SMA, is consistent with abrupt hypermethylation of ACTA2 in both ACF and MAF cells. This observation may indicate the association of epigenetic changes in the activation of ACF cells.

Cancer-associated fibroblasts, including MAFs, produce numerous bioactive substances that actively influence cancer cell proliferation, differentiation and migration ([@b15-ijmm-41-05-2687]) and are able to strongly influence melanoma cells. Furthermore, cancer-associated fibroblasts, or MAFs specifically, are important drivers of tumor progression, including metastatic spread, and resistance to vemurafenib, as proposed recently ([@b27-ijmm-41-05-2687],[@b30-ijmm-41-05-2687],[@b37-ijmm-41-05-2687]). Based on the presented similarities of MAFs and ACFs in the present patient on B-Raf inhibitor treatment, it may be hypothesized that vemurafenib therapy is able to influence not only B-Raf mutated tumor cells, but presumably may also shape the whole landscape of tissue microenvironment in the human body, to some extent. Vast differences have also been documented in control fibroblasts (ACF vs. CDF) on the level of DNA methylation, RNA transcription and also on the protein level. Such an activated microenvironment may be suitable for growth of circulating melanoma cells ([@b2-ijmm-41-05-2687],[@b4-ijmm-41-05-2687],[@b6-ijmm-41-05-2687]). The fibronectin rich \'safe haven\' may be created either by melanoma-associated fibroblasts or by distant fibroblasts activated by TGF-β1 released from B-Raf therapy-stressed melanoma cells ([@b27-ijmm-41-05-2687]-[@b31-ijmm-41-05-2687]). Mechanistically, this phenomenon may participate in the induction of resistance to the therapy as depicted in the case of the presented patient.

The key question for the future is whether the present knowledge of fibroblast heterogeneity may be of clinical use in personalized cancer therapy. As indicated above, the ACFs resemble normal dermal fibroblasts of a healthy individual stimulated by TGF-β1. Therefore, it may be hypothesized that therapeutic attenuation of TGF-β activity ([@b38-ijmm-41-05-2687],[@b39-ijmm-41-05-2687]), blocking of transition of fibroblasts to myofibroblasts ([@b39-ijmm-41-05-2687]) and/or therapeutic blockade of their function ([@b40-ijmm-41-05-2687]) may be used to prevent resistance to B-Raf inhibitor therapy in the future. Mechanistically, this blockade would disrupt bi-directional cross-talk between the melanoma cells and stromal fibroblasts which allow the tumors to amplify a drug-resistant niche. Genomic studies have clearly demonstrated the evolution of genetic heterogeneity in melanoma in the course of tumor progression and metastasis formation ([@b41-ijmm-41-05-2687],[@b42-ijmm-41-05-2687]). The tumor microenvironment seems to participate in the tumor evolution by the formation of a suitable cellular ecosystem supporting its progression ([@b43-ijmm-41-05-2687]).

The present study represents a single clinical case analysis that may be easily linked to the latest development in preclinical melanoma research on animal models ([@b28-ijmm-41-05-2687]-[@b31-ijmm-41-05-2687],[@b37-ijmm-41-05-2687],[@b38-ijmm-41-05-2687]). Larger cohort-based studies are necessary for the near future for selection of proper candidate additional targets for further improvement of personalized melanoma therapy.
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ACF

:   autologous control fibroblasts

CDF

:   control dermal fibroblasts

CT

:   computed tomography

MAF

:   melanoma associated fibroblasts

PCR

:   polymerase chain reaction

SMA

:   smooth muscle actin

TGF-β1

:   transforming growth factor-β1

![CT scan of the patient\'s chest. (A) Skin metastasis of melanoma used for the analysis (white circle). (B) Control CT scan after 3 months on vemurafenib treatment; distant uninvolved skin (white circle), a biopsy from this site was used for isolation of autologous control fibroblasts. CT, computed tomography.](IJMM-41-05-2687-g00){#f1-ijmm-41-05-2687}

![(A) Histology of malignant melanoma metastasis (biopsy from [Fig. 1A](#f1-ijmm-41-05-2687){ref-type="fig"}) with hematoxylin and eosin staining; magnification, ×200. (B) Immunohistochemical analysis (hematoxylin counterstained) confirmed smooth muscle actin-positive myofibroblasts (brown) of tumor stroma between tumor lobules and also (C) transforming growth factor β1intensely positive melanoma cells in the lobules of melanoma metastasis. (D) Negative control.](IJMM-41-05-2687-g01){#f2-ijmm-41-05-2687}

![(A) B-Raf V600E mutation was not detected in melanoma-associated fibroblasts. (B) However, this mutation was confirmed in the same metastasis. W denotes A/T mutation.](IJMM-41-05-2687-g02){#f3-ijmm-41-05-2687}

![(A) Melanoma-associated fibroblasts exhibited fibronectin (green) in the cytoplasm and sporadic cells were SMA positive (red). (B) Autologous control fibroblasts with high incidence of SMA-positive myofibroblasts in a pool of autologous fibroblasts. (C) CDFs did not contain SMA-positive cells and produced only sparse fibro fibres. (D) Stimulation of CDFs by transforming growth factor-β in culture mediaincreased transition of the fibroblasts to SMA-positive myofibroblasts, which also produced a dense fibro-positive extracellular matrix meshwork. Scale bar represents 50 mm. SMA, smooth muscle actin; fibro, fibronectin; CDF, control dermal fibroblast.](IJMM-41-05-2687-g03){#f4-ijmm-41-05-2687}

![MAFs, ACFs and CDFs differ profoundly both in their gene expression profiles and in their genome methylation profiles. (A) Projections of the expression data on the first two PCs, as determined by a PC analysis performed on expression profiles of all differentially expressed genes. PC1 reflects differences between MAF and CDF, with ACF being placed between the stromal and normal fibroblasts. (B and C) Venn diagrams display overlaps of upregulated and downregulated genes. (D) Heatmaps with a comparative analysis of MAF, ACF and CDF present a clear separation of the different fibroblast groups both in their expression profiles. (E) Projections of the methylation data on the first two PCs were plotted as determined by a PC analysis performed on methylation profiles of all differentially methylated genes. (F and G) Venn diagrams display overlaps of hyper-methylated and hypo-methylated regions in various studied comparisons. (H) MAF, ACF and CDF methylation profiles. Only differentially expressed genes and differentially methylated regions are presented. MAF, melanoma-associated fibroblast; ACF, autologous control fibroblast; CDF, control dermal fibroblast; PC, principal component.](IJMM-41-05-2687-g04){#f5-ijmm-41-05-2687}

![Changes in gene expression and methylation of selected genes with the strongest changes in gene expression and methylation. For the selected genes, heatmaps of (A) gene expression and (B) methylation of genomic regions overlapping the genes loci are presented. Methylation is expressed in terms of M-values. M=−4 \[(A) 0; (B) 4\] corresponds to \~5% \[(A) 50%; (B) 95%\] of the DNA in the methylated genomic region. MAF, melanoma-associated fibroblast; ACF, autologous control fibroblast; CDF, control dermal fibroblast.](IJMM-41-05-2687-g05){#f6-ijmm-41-05-2687}

###### 

Significantly deregulated genes that are differentially expressed in comparisons of MAFs, ACFs and CDFs.

  A, Upregulated genes, MAF vs. CDF                                                                                                                                                                              
  ----------------------------------- -------------------- ---------- ----------------------------------------------- ----------------------------------------------------------- ------- ------ ------- ------- --
  3036                                ENSG00000105509      HAS1       Hyaluronan synthase 1                           GO:0085029                                                  8E-23   4.50   7.62    4.50    
  221303                              ENSG00000183807      FAM162B    Family with sequence similarity 162, member B   --                                                          3E-22   4.48   7.85    5.10    
  3875                                ENSG00000111057      KRT18      Keratin 18                                      GO:0009653                                                  2E-20   5.45   9.76    8.93    
  894                                 ENSG00000118971 CC   ND2        Cyclin D2                                       GO:0008284                                                  2E-20   5.00   9.10    6.85    
  8076                                ENSG00000197614      MFAP5      Microfibrillar associated protein 5             GO:0030198[a](#tfn2-ijmm-41-05-2687){ref-type="table-fn"}   2E-19   7.73   12.06   12.24   
  11341                               ENSG00000164106      SCRG1      Stimulator of chondrogenesis 1                  GO:0007399                                                  2E-19   4.55   8.26    7.07    
  5909                                ENSG00000076864      RAP1GAP    RAP1 GTPase activating protein                  GO:0043087                                                  2E-19   4.50   7.59    5.10    
  353139                              ENSG00000187173      LCE2A      Late cornified envelope 2A                      GO:0030216                                                  3E-19   4.96   7.77    5.34    
  1776                                ENSG00000163687 D    NASE1L3    Deoxyribonuclease I-like 3                      GO:0006309                                                  7E-18   4.56   7.51    5.79    
  284085                              ENSG00000265480      KRT18P55   Keratin 18 pseudogene 55                        --                                                          1E-17   4.68   8.37    7.04    
  3202                                ENSG00000106004      HOXA5      Homeobox A5                                     GO:0048704[a](#tfn2-ijmm-41-05-2687){ref-type="table-fn"}   2E-17   7.30   10.72   7.39    
  1829                                ENSG00000046604 D    SG2        Desmoglein 2                                    GO:0007155                                                  6E-17   4.65   7.78    4.92    
  3887                                ENSG00000205426      KRT81      keratin 81                                      GO:0005198                                                  7E-17   5.67   8.93    6.94    

  B, Downregulated genes, MAF vs. CDF                                                                                                                                                                                      
  ------------------------------------- ------------------- ---------- ---------------------------------------------------------------- ----------------------------------------------------------- ------- ------- ------ -------
  404266                                ENSG00000233101     HOXB-AS3   HOXB cluster antisense RNA 3 (non- protein coding)               --                                                          2E-21   9.54    5.92   9.78
  8988                                  ENSG00000169271     HSPB3      Heat shock 27 kDa protein 3                                      GO:0006986                                                  6E-18   10.12   5.73   9.35
  6387                                  ENSG00000107562 C   XCL12      Chemokine (C-X-C motif) ligand 12                                GO:0001666[a](#tfn2-ijmm-41-05-2687){ref-type="table-fn"}   9E-18   10.36   4.97   10.19
  1396                                  ENSG00000213145 C   RIP1       Cysteine-rich protein 1 (intestinal)                             GO:0008283                                                  1E-17   11.03   7.10   8.73
  160364                                ENSG00000172322     CLEC12A    C-type lectin domain family 12, member A                         --                                                          2E-17   5.99    4.53   4.48
  4147                                  ENSG00000132561     MATN2      Matrilin 2                                                       GO:0008347[a](#tfn2-ijmm-41-05-2687){ref-type="table-fn"}   5E-17   10.57   6.86   9.11
  160364                                ENSG00000172322     CLEC12A    C-type lectin domain family 12, member A, transcript variant 2   --                                                          8E-17   6.64    4.51   4.55

  C, Upregulated genes, MAF vs. ACF                                                                                                                                                                                                      
  ----------------------------------- ------------------- --------- --------------------------------------------------------------------------------- ----------------------------------------------------------- ------- ------ ------- ------
  3036                                ENSG00000105509     HAS1      Hyaluronan synthase 1                                                             GO:0085029                                                  1E-22   4.50   7.62    4.50
  221303                              ENSG00000183807     FAM162B   Family with sequence similarity 162, member B                                     --                                                          3E-19   4.48   7.85    5.10
  3202                                ENSG00000106004     HOXA5     Homeobox A5                                                                       GO:0048704[a](#tfn2-ijmm-41-05-2687){ref-type="table-fn"}   7E-17   7.30   10.72   7.39
  353139                              ENSG00000187173     LCE2A     Late cornified envelope 2A                                                        GO:0030216                                                  1E-16   4.96   7.77    5.34
  5909                                ENSG00000076864     RAP1GAP   RAP1 GTPase activating protein                                                    GO:0043087                                                  5E-16   4.50   7.59    5.15
  1829                                ENSG00000046604 D   SG2       Desmoglein 2                                                                      GO:0007155                                                  5E-15   4.65   7.78    4.92
  55966                               ENSG00000196581     AJAP1     Adherens junctions associated protein 1                                           GO:0007155                                                  1E-13   4.60   6.16    4.37
  1300                                ENSG00000123500 C   OL10A1    Collagen, type X, α1                                                              GO:0030198[a](#tfn2-ijmm-41-05-2687){ref-type="table-fn"}   2E-14   5.11   7.78    4.93
  3778                                ENSG00000156113     KCNMA1    Potassium large conductance calcium- activated channel, subfamily M, α member 1   GO:0001666[a](#tfn2-ijmm-41-05-2687){ref-type="table-fn"}   2E-14   9.64   9.46    6.95
  794                                 ENSG00000172137 C   ALB2      Calbindin 2                                                                       GO:0005509                                                  8E-14   6.78   8.33    4.98

  D, Downregulated genes, MAF vs. ACF                                                                                                                                                                                     
  ------------------------------------- ------------------- ---------- --------------------------------------------------------------- ----------------------------------------------------------- ------- ------- ------ -------
  404266                                ENSG00000233101     HOXB-AS3   HOXB cluster antisense RNA 3 (non-protein coding)               --                                                          3E-21   9.54    5.92   9.78
  116154                                ENSG00000087495     PHACTR3    Phosphatase and actin regulator 3                               GO:0043086                                                  2E-19   7.40    5.32   10.49
  72                                    ENSG00000163017     ACTG2      Actin, γ2, smooth muscle, enteric                               GO:0090131                                                  2E-18   4.84    4.58   12.18
  70                                    ENSG00000159251     ACTC1      Actin, α, cardiac muscle 1                                      GO:0090131                                                  7E-17   9.89    7.27   12.76
  6387                                  ENSG00000107562 C   XCL12      Chemokine (C-X-C motif) ligand 12                               GO:0001666[a](#tfn2-ijmm-41-05-2687){ref-type="table-fn"}   7E-17   10.36   4.97   10.19
  154197                                ENSG00000146453     PNLDC1     Poly(A)-specific ribonuclease (PARN)-like domain containing 1   --                                                          3E-16   4.49    4.45   5.51
  8988                                  ENSG00000169271     HSPB3      Heat shock 27 kDa protein 3                                     GO:0006986                                                  8E-15   10.12   5.73   9.35
  90139                                 ENSG00000157570     TSPAN18    Tetraspanin 18                                                  GO:0030198                                                  8E-15   5.69    4.90   8.26
  668                                   ENSG00000183770     FOXL2      Forkhead box L2                                                 GO:0030154                                                  3E-14   7.66    4.79   8.16
  5121                                  ENSG00000183036     PCP4       Purkinje cell protein 4                                         GO:0007417                                                  1E-13   4.53    4.44   7.16

  E, Upregulated genes, ACF vs. CDF                                                                                                                                                                                                        
  ----------------------------------- ----------------- --------- ------------------------------------------------------------------------------------- ----------------------------------------------------------- ------- ------ ------- -------
  8076                                ENSG00000197614   MFAP5     Microfibrillar associated protein 5                                                   GO:0030198[a](#tfn2-ijmm-41-05-2687){ref-type="table-fn"}   2E-18   7.73   12.06   12.24
  72                                  ENSG00000163017   ACTG2     Actin, γ2, smooth muscle, enteric                                                     GO:0090131                                                  4E-17   4.84   4.58    12.18
  3875                                ENSG00000111057   KRT18     Keratin 18                                                                            GO:0009653                                                  4E-16   5.45   9.76    8.93
  85409                               ENSG00000145506   NKD2      Naked cuticle homolog 2 (*Drosophila*)                                                GO:0030178                                                  7E-16   4.45   7.27    7.70
  154197                              ENSG00000146453   PNLDC1    Poly(A)-specific ribonuclease (PARN)-like domain containing 1                         --                                                          2E-15   4.49   4.45    5.51
  8322                                ENSG00000174804   FZD4      Frizzled family receptor 4                                                            GO:0060070                                                  3E-15   6.85   8.31    9.66
  64798                               ENSG00000155792   DEPTOR    DEP domain containing MTOR-interacting protein                                        GO:0035556                                                  1E-13   4.79   6.71    8.64
  11341                               ENSG00000164106   SCRG1     Stimulator of chondrogenesis 1                                                        GO:0007399                                                  2E-13   4.55   8.26    7.07
  54518                               ENSG00000077420   APBB1IP   Amyloid beta (A4) precursor protein-binding. family B, member 1 interacting protein   GO:0045785[a](#tfn2-ijmm-41-05-2687){ref-type="table-fn"}   2E-13   7.60   9.39    9.57
  157506                              ENSG00000121039   RDH10     Retinol dehydrogenase 10 (all-trans)                                                  GO:0014032                                                  3E-13   7.38   9.37    10.58
  5121                                ENSG00000183036   PCP4      Purkinje cell protein 4                                                               GO:0007417                                                  3E-13   4.53   4.44    7.16
  3751                                ENSG00000184408   KCND2     Potassium voltage-gated channel. Shal-related subfamily, member 2                     GO:0071456                                                  3E-13   4.42   6.28    6.14

  F, Downregulated genes, ACF vs. CDF                                                                                                                                                                                                    
  ------------------------------------- ----------------- ---------- -------------------------------------------------------------------------------- ----------------------------------------------------------- ------- ------- ------ ------
  4885                                  ENSG00000106236   NPTX2      Neuronal pentraxin II                                                            --                                                          4E-17   9.10    6.41   5.30
  100133941                             ENSG00000272398   CD24       CD24 molecule                                                                    GO:0002237[a](#tfn2-ijmm-41-05-2687){ref-type="table-fn"}   3E-16   10.02   7.09   6.68
  160364                                ENSG00000172322   CLEC12A    C-type lectin domain family 12. member A                                         --                                                          4E-16   5.99    4.53   4.48
  160364                                ENSG00000172322   CLEC12A    C-type lectin domain family 12. member A. transcript variant 2                   --                                                          1E-15   6.64    4.51   4.55
  3778                                  ENSG00000156113   KCNMA1     Potassium large conductance calcium-activated channel. Subfamily M. α member 1   GO:0001666[a](#tfn2-ijmm-41-05-2687){ref-type="table-fn"}   9E-15   9.64    9.46   6.95
  84675                                 ENSG00000147573   TRIM55     Tripartite motif containing 55                                                   GO:0007165                                                  3E-13   6.31    4.70   4.47
  6228                                  ENSG00000186468   RPS23      Ribosomal protein S23                                                            GO:0005840                                                  6E-13   11.47   8.85   8.83
  85352                                 ENSG00000138944   KIAA1644   KIAA1644                                                                         --                                                          7E-13   9.68    6.61   7.14

The 20 most marked DEGs are listed.

Listed among GO terms enriched by DEGs as identified by gene set enrichment analysis. Significance level, FDR\<0.05. MAF, melanoma-associated fibroblast; ACF, autologous control fibroblast; CDF, control dermal fibroblast; FDR, false discovery rate; DEG, differentially expressed gene; GO BP, gene ontology biological process.

###### 

Results of gene set enrichment analysis performed on differentially expressed genes and GO BP terms.

  A, (MAF and ACF) vs. CDF                                                                          
  -------------------------- ------------------------------------------------------------- -------- ---------
  GO:0030198                 Extracellular matrix organization                             35/359   0.00091
  GO:0043062                 Extracellular structure organization                          35/360   0.00091
  GO:0001936                 Regulation of endothelial cell proliferation                  15/88    0.00335
  GO:0010574                 Regulation of vascular endothelial growth factor production   8/27     0.01791
  GO:0002237                 Response to molecule of bacterial origin                      24/243   0.01791
  GO:0009611                 Response to wounding                                          19/167   0.01791
  GO:0051272                 Positive regulation of cellular component movement            27/296   0.01791
  GO:0040017                 Positive regulation of locomotion                             27/304   0.02116
  GO:2000147                 Positive regulation of cell motility                          26/287   0.02116
  GO:0001503                 Ossification                                                  15/116   0.02116
  GO:0008347                 Glial cell migration                                          6/15     0.02116
  GO:0045765                 Regulation of angiogenesis                                    19/179   0.02490
  GO:0032496                 Response to lipopolysaccharide                                22/228   0.02490
  GO:0030335                 Positive regulation of cell migration                         25/280   0.02511
  GO:0030111                 Regulation of Wnt signaling pathway                           21/214   0.02515
  GO:0060828                 Regulation of canonical Wnt signaling pathway                 17/152   0.02544
  GO:0051894                 Positive regulation of focal adhesion assembly                6/18     0.02978
  GO:1901890                 Positive regulation of cell junction assembly                 6/18     0.02978
  GO:0001937                 Negative regulation of endothelial cell proliferation         7/27     0.02978

  B, (CDF and ACF) vs. MAF                                                                 
  -------------------------- ---------------------------------------------------- -------- ---------
  GO:0048729                 Tissue morphogenesis                                 44/358   0.00023
  GO:0051272                 Positive regulation of cellular component movement   39/296   0.00023
  GO:0030198                 Extracellular matrix organization                    44/359   0.00023
  GO:0043062                 Extracellular structure organization                 44/360   0.00023
  GO:2000147                 Positive regulation of cell motility                 37/287   0.00055
  GO:0030335                 Positive regulation of cell migration                36/280   0.00068
  GO:0048598                 Embryonic morphogenesis                              45/403   0.00094
  GO:0040017                 Positive regulation of locomotion                    37/304   0.00118
  GO:0030155                 Regulation of cell adhesion                          39/336   0.00158
  GO:0002009                 Morphogenesis of an epithelium                       35/296   0.00312
  GO:0048562                 Embryonic organ morphogenesis                        20/121   0.00400
  GO:0048704                 Embryonic skeletal system morphogenesis              16/81    0.00403
  GO:0045785                 Positive regulation of cell adhesion                 24/171   0.00507
  GO:0036293                 Response to decreased oxygen levels                  30/245   0.00507
  GO:0009887                 Organ morphogenesis                                  42/405   0.00507
  GO:0070482                 Response to oxygen levels                            31/259   0.00516
  GO:0071294                 Cellular response to zinc ion                        7/14     0.00770
  GO:0001666                 Response to hypoxia                                  29/241   0.00770
  GO:0022617                 Extracellular matrix disassembly                     18/116   0.01315
  GO:0048705                 Skeletal system morphogenesis                        17/106   0.01380

The \'best\' 20 ontology terms are provided for each comparison (i.e. corresponds to the terms with an adjusted P-value of the enrichment test ≥0.03). GO BP, gene ontology biological process; MAF, melanoma-associated fibroblast; ACF, autologous control fibroblast; CDF, control dermal fibroblast.

###### 

DMRs between fibroblast groups.

  A, Hyper-methylated genes in MAF vs. CDF                                                                                                             
  ------------------------------------------ -------- -------- ------------------------------------------------- ------------ --------- ------- ------ -------
  NM_001141945                               59       ACTA2    Actin, α2, smooth muscle, aorta                   GO:0090131   6.0E-07   −3.48   3.43   1.72
  NM_006308                                  8988     HSPB3    Heat shock 27 kDa protein 3                       --           7.6E-07   −3.32   3.07   2.09
  NM_001202233                               3164     NR4A1    Nuclear receptor subfamily 4. group A, member 1   GO:0044344   7.6E-07   0.07    4.86   4.06
  NM_031950                                  83888    FGFBP2   Fibroblast growth factor binding protein 2        --           7.6E-07   −3.13   1.69   −2.15
  NM_001307983                               130013   ACMSD    Aminocarboxymuconate semialdehyde decarboxylase   GO:1905004   7.6E-07   −2.15   3.15   1.12
  NM_001256552                               79661    NEIL1    Nei-like DNA glycosylase 1                        GO:0010730   7.6E-07   −1.86   3.19   0.87
  NM_001039469                               2011     MARK2    MAP/microtubule affinity-regulating kinase 2      GO:0016055   7.6E-07   −3.05   1.15   1.01
  NM_001193341                               221421   RSPH9    Radial spoke head 9 homolog (Chlamydomonas)       GO:0044458   7.6E-07   −3.74   0.46   −2.33
  NM_033199                                  90226    UCN2     Urocortin 2                                       GO:0031669   7.6E-07   −3.43   1.19   0.14

  B, Hypo-methylated genes in MAF vs. CDF                                                                                                                                                    
  ----------------------------------------- ------------- --------- ----------------------------------- ----------------------------------------------------------- --------- ------ ------- -------
  NM_001199505                              116154        PHACTR3   Phosphatase and actin regulator 3   GO:0043086                                                  7.6E-07   3.37   −2.73   0.74
  NM_144719                                 152206 CCDC   13        Coiled-coil domain containing 13    GO:0035058                                                  7.6E-07   2.05   −2.57   −0.17
  NM_000438                                 5077          PAX3      Paired box 3                        GO:0009887[a](#tfn2-ijmm-41-05-2687){ref-type="table-fn"}   7.6E-07   2.96   −1.53   2.98
  NM_002151                                 3249          HPN       Hepsin                              GO:0010719                                                  7.6E-07   4.09   −1.15   1.34
  NM_153038                                 151278 CCDC   140       Coiled-coil domain containing 140   --                                                          7.6E-07   2.40   −2.86   2.87
  NM_000384                                 338           APOB      Apolipoprotein B                    GO:0032496[a](#tfn2-ijmm-41-05-2687){ref-type="table-fn"}   7.6E-07   2.90   −2.93   0.66

  C, Hyper-methylated genes in MAF vs. ACF                                                                                                                                                                                     
  ------------------------------------------ -------- ---------- ----------------------------------------------------------------------- ----------------------------------------------------------- --------- ------- ------- -------
  NM_001242805                               676      BRDT       Bromodomain, testis-specific                                            GO:0006338                                                  4.2E-06   1.15    3.62    −1.43
  NM_001300905                               11176    BAZ2A      Bromodomain adjacent to zinc finger domain, 2A                          GO:0006338                                                  5.1E-06   −4.52   −0.9    −4.29
  NM_018593                                  117247   SLC16A10   Solute carrier family 16 (aromatic amino acid transporter). Member 10   GO:0006865                                                  4.2E-06   −3.50   1.46    −3.98
  NM_005992                                  6899     TBX1       T-box 1                                                                 GO:0001525                                                  4.2E-06   0.79    1.60    −2.20
  NM_178818                                  146223   CMTM4      CKLF-like MARVEL transmembrane domain containing 4                      GO:0005125                                                  4.2E-06   −2.70   1.35    −2.46
  NM_000663                                  18       ABAT       4-aminobutyrate aminotransferase                                        GO:0001666[a](#tfn2-ijmm-41-05-2687){ref-type="table-fn"}   4.2E-06   −4.14   −0.07   −4.11
  NM_006829                                  10974    ADIRF      Adipogenesis regulatory factor                                          GO:0030154                                                  4.2E-06   −4.29   0.31    −4.32
  NM_006181                                  4917     NTN3       Netrin 3                                                                GO:0007411                                                  4.2E-06   −4.54   −1.14   −4.78
  NM_031950                                  83888    FGFBP2     Fibroblast growth factor binding protein 2                              --                                                          4.7E-06   −3.13   1.69    −2.15
  NM_001720                                  656      BMP8B      Bone morphogenetic protein 8b                                           GO:0001503[a](#tfn2-ijmm-41-05-2687){ref-type="table-fn"}   4.7E-06   −4.66   −0.79   −4.55
  NM_005731                                  10109    ARPC2      Actin related protein 2/3 complex. subunit 2, 34 kDa                    GO:1900026                                                  5.1E-06   −3.37   −0.84   −4.31

  D, Hypo-methylated genes in MAF vs. ACF                                                                                                                                                   
  ----------------------------------------- ------------- ------- ----------------------------------- ----------------------------------------------------------- --------- ------- ------- -------
  NM_000192                                 6910          TBX5    T-box 5                             GO:0002009[a](#tfn2-ijmm-41-05-2687){ref-type="table-fn"}   1.3E-06   −2.27   −3.24   3.75
  NM_153038                                 151278 CCDC   140     Coiled-coil domain containing 140   --                                                          3.4E-06   2.40    −2.86   2.87
  NM_000438                                 5077          PAX3    Paired box 3                        GO:0009887[a](#tfn2-ijmm-41-05-2687){ref-type="table-fn"}   4.2E-06   2.96    −1.53   2.98
  NM_001053                                 6755          SSTR5   Somatostatin receptor 5             GO:0007186                                                  4.2E-06   −0.75   −4.83   −0.62
  NM_152739                                 3205          HOXA9   Homeobox A9                         GO:0007275                                                  4.2E-06   0.09    −3.76   0.28
  NM_015916                                 51063 C       ALHM2   Calcium homeostasis modulator 2     GO:0005261                                                  5.1E-06   −4.79   −4.84   −1.16

  E, Hyper-methylated genes in ACF vs. CDF                                                                                                                                                            
  ------------------------------------------ ------- -------- ------------------------------------------------- ----------------------------------------------------------- --------- ------- ------- -------
  NM_000192                                  6910    TBX5     T-box 5                                           GO:0002009[a](#tfn2-ijmm-41-05-2687){ref-type="table-fn"}   3.6E-06   −2.27   −3.24   3.75
  NM_001141945                               59      ACTA2    Actin. α2, smooth muscle, aorta                   GO:0090131                                                  3.6E-06   −3.48   3.43    1.72
  NM_006308                                  8988    HSPB3    Heat shock 27 kDa protein 3                       --                                                          3.6E-06   −3.32   3.07    2.09
  NM_001039469                               2011    MARK2    MAP/microtubule affinity-regulating kinase 2      GO:0016055                                                  3.6E-06   −3.05   1.15    1.01
  NM_001202233                               3164    NR4A1    Nuclear receptor subfamily 4. group A. member 1   GO:0044344                                                  4.0E-06   0.07    4.86    4.06
  NM_000129                                  2162    F13A1    Coagulation factor XIII. A1 polypeptide           GO:0007596                                                  4.0E-06   −4.97   −0.78   −1.12
  NM_001286555                               56940   DUSP22   Dual specificity phosphatase 22                   GO:0008283                                                  5.9E-06   −3.92   −0.45   −0.51
  NM_015916                                  51063   CALHM2   Calcium homeostasis modulator 2                   GO:0005261                                                  5.9E-06   −4.79   −4.84   −1.16
  NM_001012631                               9235    IL32     Interleukin 32                                    GO:0005125                                                  5.9E-06   −3.35   0.37    1.29
  NM_000504                                  2159    F10      Coagulation factor X                              GO:0030335[a](#tfn2-ijmm-41-05-2687){ref-type="table-fn"}   6.2E-06   −0.42   3.59    3.68

  F, Hypo-methylated genes in ACF vs. CDF                                                                                                        
  ----------------------------------------- -------- -------- ------------------------------------------- ------------ --------- ------- ------- -------
  NM_001297436                              3036     HAS1     Hyaluronan synthase 1                       GO:0085029   4.0E-06   1.38    −4.34   −4.22
  NM_000965                                 5915     RARB     Retinoic acid receptor, beta                GO:0007165   4.0E-06   −0.57   −4.43   −4.66
  NM_001166247                              2898     GRIK2    Glutamate receptor, ionotropic, kainate 2   GO:0046328   4.0E-06   0.73    −3.46   −3.40
  NM_001207011                              1271     CNTFR    Ciliary neurotrophic factor receptor        GO:0060538   5.8E-06   2.87    −2.6    −1.69
  NM_001128423                              255027   MPV17L   MPV17 mitochondrial membrane protein-like   GO:0010730   6.3E-06   −0.75   −3.91   −4.53

The 15 most marked DMRs with FDR\<0.1 and \|log~2~FC\|\>1 are listed.

Listed among GO terms enriched by differentially expressed genes as identified by gene set enrichment analysis. DMR, differentially methylated genomic region; FDR, false discovery rate; M-value, methylation M-value; GO BP, gene ontology biological process; MAF, melanoma-associated fibroblast; ACF, autologous control fibroblast; CDF, control dermal fibroblast.
